<DOC>
	<DOCNO>NCT00133224</DOCNO>
	<brief_summary>The primary objective study compare duration survival patient receive docetaxel combination GVAX® vaccine prostate cancer versus patient receive docetaxel prednisone treatment patient prostate cancer long respond hormone therapy , document metastasis pain . Patients may one prior non-taxane chemotherapy treatment .</brief_summary>
	<brief_title>Docetaxel Combination With GVAX ® Immunotherapy Versus Docetaxel Prednisone Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Confirmed diagnosis clinical history consistent adenocarcinoma prostate Metastatic prostate cancer deem unresponsive refractory hormone therapy Detectable metastasis ECOG performance status ≤2 ( Performance status 3 due bone pain ) Any Gleason score Only one prior treatment systemic chemotherapy No prior treatment gene therapy No prior immunotherapy prostate cancer Taxane naïve Experiencing cancerrelated pain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cell</keyword>
</DOC>